NKG2A&CD94 hFc Chimera, Flag, Human
NKG2A&CD94 HFc Chimera, Flag, Human

Immobilized NKG2A&CD94 hFc Chimera, Flag, Human, hFc Tag at 2 μg /ml (100 μl/well) on the hFc Antibody precoated plate(2 μg /ml). Dose response curve for Biotinylated Anti-NKG2A Antibody, hFc Tag with the EC50 of 14.1ng/ml determined by ELISA.

NKG2A&CD94 HFc Chimera, Flag, Human

The purity of NKG2A&CD94 hFc Chimera, Flag, Human is greater than 95% as determined by SEC-HPLC.

NKG2A&CD94 HFc Chimera, Flag, Human

NKG2A&CD94 hFc Chimera, Flag, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

NKG2A&CD94 hFc Chimera, Flag, Human

The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies
Z05682
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Flag hFc NKG2A&CD94 (Arg100-Leu233(NKG2A)&Ser34-Ile179(CD94))_x000D_
Accession # P26715-1(NKG2A)&Q13241-1(CD94)
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 41.1 kDa (NKG2A)&17.9 kDa (CD94)
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • NKG2A&CD94 HFc Chimera, Flag, Human
    • NKG2A&CD94 HFc Chimera, Flag, Human

    Immobilized NKG2A&CD94 hFc Chimera, Flag, Human, hFc Tag at 2 μg /ml (100 μl/well) on the hFc Antibody precoated plate(2 μg /ml). Dose response curve for Biotinylated Anti-NKG2A Antibody, hFc Tag with the EC50 of 14.1ng/ml determined by ELISA.

  • NKG2A&CD94 HFc Chimera, Flag, Human
    • NKG2A&CD94 HFc Chimera, Flag, Human

    The purity of NKG2A&CD94 hFc Chimera, Flag, Human is greater than 95% as determined by SEC-HPLC.

  • NKG2A&CD94 HFc Chimera, Flag, Human
    • NKG2A&CD94 HFc Chimera, Flag, Human

    NKG2A&CD94 hFc Chimera, Flag, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies
Synonyms CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.